Results 1 to 10 of about 32,738 (290)

Simulating drug penetration during hyperthermic intraperitoneal chemotherapy [PDF]

Drug Delivery, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC) is administered to treat residual microscopic disease after debulking cytoreductive surgery. During HIPEC, a limited number of catheters are used to administer and drain fluid containing chemotherapy (41 ...
Daan R. Löke, Roxan F. C. P. A. Helderman, Nicolaas A. P. Franken, Arlene L. Oei, Pieter J. Tanis, Johannes Crezee, H. Petra Kok   +6 more
doaj   +4 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer [PDF]

New England Journal of Medicine, 2018
(Abstracted from N Engl J Med 2018;378:230–240) The majority of patients with ovarian cancer (OC) receive an initial diagnosis of advanced disease that has spread from the ovaries to the peritoneal surface. The most effective treatment for patients with advanced disease is cytoreductive surgery followed by systemic chemotherapy.
Ceresoli, M, Frigerio, L, Ansaloni, L
semanticscholar   +18 more sources

Intra-Abdominal Desmoplastic Small Round Cell Tumor (DSRCT) and the Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Review

Current Oncology, 2023
Desmoplastic small round cell tumor is a very rare and highly aggressive soft tissue sarcoma, usually presenting with multiple intra-abdominal tumors in young males. Patients present with advanced disease and the overall survival is dismal.
Sophie J. M. Reijers, Caroline C. H. Siew, Niels F. M. Kok, Charles Honoré, Winan J. van Houdt   +4 more
doaj   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy: A Critical Review [PDF]

Cancers, 2021
With increasing awareness amongst physicians and improved radiological imaging techniques, the peritoneal cavity is increasingly recognized as an important metastatic site in various malignancies. Prognosis of these patients is usually poor as traditional treatment including surgical resection or systemic treatment is relatively ineffective ...
Wim Ceelen, Jesse Demuytere, Ignace de Hingh   +2 more
openaire   +6 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer [PDF]

Diagnostics, 2020
Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual ...
McKayla J. Riggs, Prakash K. Pandalai, Joseph Kim, Charles S. Dietrich   +3 more
doaj   +3 more sources

Anesthetic implications in hyperthermic intraperitoneal chemotherapy

Journal of Anaesthesiology Clinical Pharmacology, 2019
Patients with peritoneal carcinomatosis were considered incurable with dismal survival rates till hyperthermic intraperitoneal chemotherapy after optimal cytoreductive surgery evolved. Perioperative management for these procedures is complex and involves
Nishkarsh Gupta, Vinod Kumar, Rakesh Garg, Sachidanand Jee Bharti, Seema Mishra, Sushma Bhatnagar   +5 more
doaj   +3 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Annals of Surgical Oncology, 2023
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality
Julia H, Gelissen, Naomi N, Adjei, Blair, McNamara, Levent, Mutlu, Justin A, Harold, Mitchell, Clark, Gary, Altwerger, Peter R, Dottino, Gloria S, Huang, Alessandro D, Santin, Masoud, Azodi, Elena, Ratner, Peter E, Schwartz, Vaagn, Andikyan   +13 more
openaire   +3 more sources

Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Emma S. Zwanenburg, Charlotte E.L. Klaver, D D Wisselink, Cornelis J.A. Punt, Pétur Snæbjörnsson, Johannes Crezee, Arend G. J. Aalbers, Alexandra R. M. Brandt‐Kerkhof, André J. A. Bremers, Pim J. W. A. Burger, Hans F. J. Fabry, Floris Ferenschild, Sebastiaan Festen, Wilhemina M.U. van Grevenstein, Patrick Hemmer, Ignace H. J. T. de Hingh, Niels F. M. Kok, Miranda Kusters, G.D. Musters, Lotte Schoonderwoerd, Jurriaan B. Tuynman, Anthony W. H. van de Ven, Henderik L. van Westreenen, Marinus J. Wiezer, D. D. E. Zimmerman, Annette van Zweeden, Marcel G. W. Dijkgraaf, Pieter J. Tanis, Caroline S. Andeweg, Vivian P. Bastiaenen, Willem A. Bemelman, Jarmila D.W. van der Bilt, Johanne G. Bloemen, Frank C. den Boer, Djamila Boerma, Daan ten Bokkel Huinink, Walter J.A. Brokelman, Huib A. Cense, Esther C. J. Consten, Geert-Jan Creemers, Rogier M. P. H. Crolla, Jan‐Willem T. Dekker, Jennifer Demelinne, Marc J. van Det, Karin K. van Diepen, Marjolein Diepeveen, Eino B. van Duyn, Esther D. van den Ende, Pauline Evers, Anna A. W. van Geloven, Erwin van der Harst, Jeroen Heemskerk, Joost T. Heikens, Daniël A. Hess, Bas Inberg, Jan B.�M.�J. Jansen, Frank W.H. Kloppenberg, Thomas J.M. Kootstra, R.T.J. Kortekaas, Maartje Los, Eva V. E. Madsen, H.C.J. van der Mijle, Linda Mol, Peter A. Neijenhuis, Simon W. Nienhuijs, Loes van den Nieuwenhof, Koen Peeters, Sebastiaan W. Polle, Jolien Pon, Pieter Poortman, Sandra A. Radema, Bert van Ramshorst, Philip R. de Reuver, Koen P. Rovers, Roderick F. Schmitz, Nina R. Sluiter, Dirkje W. Sommeijer, Eric Sonneveld, T.C. van Sprundel, Sanne C. Veltkamp, Maarten Vermaas, Victor J. Verwaal, Emma C. E. Wassenaar, Johannes A. Wegdam, Johannes H.W. de Wilt, Marinke Westerterp, Fennie Wit, Arjen J. Witkamp, Karlijn Woensdregt, Edwin S. van der Zaag, Mandy Zournas, Mandy Zournas   +91 more
openalex   +3 more sources

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures [PDF]

JAMA Network Open, 2019
Key Points Question What are the morbidity and mortality of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) compared with other major oncologic surgical procedures?
Jason M. Foster, Richard Sleightholm, Asish Patel, Valerie Shostrom, Bradley R. Hall, Beth K. Neilsen, David L. Bartlett, Lynette M. Smith   +7 more
openalex   +2 more sources

Anastomosis versus rectal stump procedure in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal peritoneal metastases: A comparative study. [PDF]

Colorectal Dis
Abstract Aim Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for peritoneal metastases (PM) of colorectal or appendiceal origin. Rectal anastomotic leakage (RAL) or rectal stump blow‐out is a serious complication following rectal resection after CRS‐HIPEC. This study aimed to compare outcomes
Ghanipour L, Mahmmud LO, Cashin P, Palmer GJ, Abraham-Nordling M.   +4 more
europepmc   +2 more sources